Eikon Therapeutics, Inc.

EIKN Nasdaq SEC CIK 1861123
Follow Eikon Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$86.1M −21% vs same quarter last year
EPS, diluted −$1.59 +93.4% vs same quarter last year
Operating cash flow −$69.2M −16.2% vs same quarter last year
Operating income −$90.6M −21.1% vs same quarter last year
Net income by quarter
−$68.2M
−$105.2M
−$71.1M
−$83M
−$88.4M
−$86.1M
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing